SERVImed - Prossimi Eventi

SERVImed sarà espositore ai prossimi eventi:

- 94° Congresso Nazionale SOI, dal 28 Novembre al 2 Dicembre all'Hotel Hilton Rome Cavalieri, stand 13 bis

- International CXL Experts' Meeting, dal 29 Novembre al 1 Dicembre all'Hotel Mövenpick Airport
Zürich.

Venite a trovarci per scoprire le ultime novità sui nostri prodotti oftalmici.

Per maggiori informazioni sui congressi: sito SOI / sito CXL.

Per scoprire la nostra linea di prodotti oftalmici, clicca QUI.

[fusion_builder_container backgroundcolor="" backgroundimage="" backgroundrepeat="no-repeat" backgroundposition="left top" backgroundattachment="scroll" video_webm="" video_mp4="" video_ogv="" video_preview_image="" overlay_color="" overlay_opacity="0.5" video_mute="yes" video_loop="yes" fade="no" bordersize="0px" bordercolor="" borderstyle="" paddingtop="20px" paddingbottom="20px" paddingleft="0px" paddingright="0px" menu_anchor="" equal_height_columns="no" hundred_percent="no" class="" id=""][fusion_builder_row][fusion_builder_column type="1_1" background_position="left top" background_color="" border_size="" border_color="" border_style="solid" spacing="yes" background_image="" background_repeat="no-repeat" padding="" margin_top="0px" margin_bottom="0px" class="" id="" animation_type="" animation_speed="0.3" animation_direction="left" hide_on_mobile="no" center_content="no" min_height="none"][fusion_text]The neuroAD system by Neuronix is an innovative, safe and effective non-pharmaceutical treatment alternative for mild to moderate Alzheimer’s Disease. It is the first medical device in the world cleared for this indication.

• Shown to slow the degenerative progression of Alzheimer’s Disease.
• Evidenced safe and effective in peer-reviewed studies
• Discovered to be superior to existing pharmaceuticals in the treatment of Alzheimer’s Disease
• Regulatory (CE) approved technology for “treatment of mild to moderate Alzheimer’s Disease”
• Known and described in literature mechanism of action
• Ongoing clinical trials in Alzheimer’s patients and active R&D
• Endorsed and backed by strong Scientific Advisory Board
• Clinical Data
  In clinical trials, neuroAD technology has shown measurable cognitive improvement after just a few weeks. The results showed marked reversal of disease progression.

[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]